HR-20013

Primary objective: To evaluate the pharmacokinetic differences of HR20013 for injection in subjects with moderate (Child-Pugh B) liver function impairment and subjects with normal liver function, and to provide a basis for formulating clinical medication regimens for patients with liver function impairment. Secondary objective: To evaluate the safety and tolerability of HR20013 after a single infusion in subjects with moderate liver function impairment and subjects with normal liver function.

(1) To evaluate the pharmacokinetic characteristics of HR20013 after multiple intravenous injections in healthy subjects. (2) To evaluate the safety of HR20013 after multiple intravenous injections in healthy subjects.